https://vettapharma.com/pharmaceutical-news/mannkind-advances-nintedanib-dpi-trials-for-idiopathic-pulmonary-fibrosis/ 2026-06-03T16:26:34Z VETTAPHARMA en MannKind Advances Nintedanib DPI Trials for Idiopathic Pulmonary Fibrosis 2026-06-03T16:26:29Z Blog https://vettapharma.com/pharmaceutical-news/ema-and-ama-join-forces-to-combat-bundibugyo-ebola-outbreak/ 2026-06-03T16:23:50Z VETTAPHARMA en EMA and AMA Join Forces to Combat Bundibugyo Ebola Outbreak 2026-06-03T16:23:46Z Blog https://vettapharma.com/pharmaceutical-news/amgen-to-present-new-uplizna-and-tavneos-data-at-eular-2026/ 2026-06-03T16:23:44Z VETTAPHARMA en Amgen To Present New UPLIZNA and TAVNEOS Data at EULAR 2026 2026-06-03T16:23:39Z Blog https://vettapharma.com/pharmaceutical-news/sanofi-expands-accelrare-platform-with-biogen-to-speed-rare-disease-diagnosis/ 2026-06-03T16:23:40Z VETTAPHARMA en Sanofi Expands accelRare Platform With Biogen to Speed Rare Disease Diagnosis 2026-06-03T16:23:34Z Blog https://vettapharma.com/pharmaceutical-news/fda-approves-mannkinds-afrezza-expanding-needle-free-mealtime-insulin-access-for-children/ 2026-06-02T12:04:37Z VETTAPHARMA en FDA Approves MannKind’s Afrezza Expanding Needle-Free Mealtime Insulin Access for Children 2026-06-02T12:04:32Z Blog https://vettapharma.com/pharmaceutical-news/fda-priority-review-puts-roches-giredestrant-on-track-to-transform-early-breast-cancer/ 2026-06-02T10:11:11Z VETTAPHARMA en FDA Priority Review Puts Roche’s Giredestrant on Track to Transform Early Breast Cancer 2026-06-02T10:30:00Z Blog https://vettapharma.com/pharmaceutical-news/moderna-and-cepi-collaborate-to-develop-ebolavirus-vaccine/ 2026-06-02T10:27:43Z VETTAPHARMA en Moderna and CEPI Collaborate to Develop Ebolavirus Vaccine 2026-06-02T10:30:00Z Blog https://vettapharma.com/pharmaceutical-news/european-commission-approves-amgens-imdylltra-following-40-survival-advantage-in-sclc/ 2026-06-02T10:29:42Z VETTAPHARMA en European Commission Approves Amgen's IMDYLLTRA Following 40% Survival Advantage in SCLC 2026-06-02T10:30:00Z Blog https://vettapharma.com/pharmaceutical-news/asco-data-show-novartis-scemblix-sustains-long-term-efficacy-in-chronic-myeloid-leukemia/ 2026-06-02T10:06:51Z VETTAPHARMA en ASCO Data Show Novartis' Scemblix Sustains Long-Term Efficacy in Chronic Myeloid Leukemia 2026-06-02T10:00:00Z Blog